Performance of ADMA ADMA Biologics | 507.5% in 12m
Compare ADMA with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare ADMA Biologics with its related Sector/Index XBI
Performance Duell ADMA vs XBI
| TimeFrame | ADMA | XBI |
|---|---|---|
| 1 Week | 4.67% | -0.93% |
| 1 Month | 20.3% | -1.01% |
| 3 Months | 77.1% | 6.34% |
| 6 Months | 223.1% | 9.11% |
| 12 Months | 507.5% | 36.28% |
| YTD | 345.9% | 8.22% |
| Rel. Perf. 1m | 1.82 | |
| Rel. Perf. 3m | 6.79 | |
| Rel. Perf. 6m | 11.03 | |
| Rel. Perf. 12m | 11.03 | |
| Spearman 1m | 0.81 | -0.25 |
| Spearman 3m | 0.86 | 0.12 |
Is ADMA Biologics a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, ADMA Biologics (NASDAQ:ADMA) is currently (October 2024)
a good stock to buy. It has a ValueRay Fundamental Rating of 83.64 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ADMA as of October 2024 is 39.79. This means that ADMA is currently undervalued and has a potential upside of +96.11% (Margin of Safety).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ADMA as of October 2024 is 39.79. This means that ADMA is currently undervalued and has a potential upside of +96.11% (Margin of Safety).
Is ADMA a buy, sell or hold?
- Strong Buy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
Values above 0%: ADMA is performing better - Values below 0%: ADMA is underperforming
Compare ADMA with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 4.41% | 15.95% | 210.71% | 473.15% |
| US NASDAQ 100 | QQQ | 4.55% | 14.32% | 210.81% | 473.63% |
| US Dow Jones Industrial 30 | DIA | 4.56% | 16.80% | 212.47% | 479.24% |
| German DAX 40 | DBXD | 6.49% | 17.38% | 219.62% | 482.13% |
| UK FTSE 100 | ISFU | 7.39% | 20.31% | 213.67% | 487.76% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -15.42% | -22.24% | 189.19% | 477.12% |
| Hongkong Hang Seng | HSI | -2.27% | -6.26% | 191.33% | 486.00% |
| Japan Nikkei 225 | EXX7 | 3.42% | 15.40% | 223.60% | 488.84% |
| India NIFTY 50 | INDA | 8.10% | 21.05% | 212.37% | 477.98% |
| Brasil Bovespa | EWZ | 5.75% | 20.84% | 228.42% | 501.89% |
ADMA ADMA Biologics vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 3.70% | 13.42% | 211.21% | 471.65% |
| Consumer Discretionary | XLY | 6.00% | 12.95% | 211.19% | 483.22% |
| Consumer Staples | XLP | 6.54% | 22.16% | 211.89% | 481.97% |
| Energy | XLE | -2.20% | 13.24% | 225.50% | 498.69% |
| Financial | XLF | 3.56% | 19.47% | 211.39% | 467.15% |
| Health Care | XLV | 5.57% | 23.09% | 215.45% | 489.42% |
| Industrial | XLI | 4.17% | 14.62% | 213.03% | 473.07% |
| Materials | XLB | 6.48% | 16.09% | 218.62% | 483.18% |
| Real Estate | XLRE | 6.41% | 20.10% | 206.98% | 475.00% |
| Technology | XLK | 4.59% | 12.63% | 212.32% | 473.26% |
| Utilities | XLU | 3.56% | 13.72% | 196.08% | 462.23% |
| Aerospace & Defense | XAR | 3.03% | 15.30% | 206.51% | 468.63% |
| Biotech | XBI | 5.60% | 21.28% | 213.98% | 471.21% |
| Homebuilder | XHB | 7.03% | 12.75% | 209.50% | 446.27% |
| Retail | XRT | 5.99% | 16.47% | 219.21% | 475.98% |
Does ADMA Biologics outperform its market, is ADMA a Sector Leader?
Yes, over the last 12 months ADMA Biologics (ADMA) made 507.49%, while its related Sector, the SPDR S&P Biotech (XBI) made 36.28%.
Over the last 3 months ADMA made 77.05%, while XBI made 6.34%.
Yes, over the last 12 months ADMA Biologics (ADMA) made 507.49%, while its related Sector, the SPDR S&P Biotech (XBI) made 36.28%.
Over the last 3 months ADMA made 77.05%, while XBI made 6.34%.
| Period | ADMA | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 20.27% | -1.01% | 4.32% |
| 3 Months | 77.05% | 6.34% | 3.62% |
| 12 Months | 507.49% | 36.28% | 34.34% |